Literature DB >> 18433342

The role of hepatic transporters in drug elimination.

Christoph Funk1.   

Abstract

BACKGROUND: Hepatic drug transporters of the solute carrier (OATPs, OAT2, OCT1, NTCP) and ABC transporter superfamilies (MDR1, MRPs, BCRP, BSEP) can significantly modulate drug ADME routes.
OBJECTIVE: The currently available literature was reviewed with focus on hepatic drug transporters, related drug-drug interactions and available tools for transporter assessment and extrapolation to in vivo.
CONCLUSIONS: Hepatic drug transporters have gained additional importance in drug clearance by optimization for basic DMPK properties early on in drug research. However, the lack of selective substrates and inhibitors, proper assessment of the kinetic properties due to interfering passive permeability and multiple binding sites, as well as endogenous transporters present in many cellular assays, are some of the hurdles in studying active drug transport processes. Therefore, data from these in vitro assays have to be carefully evaluated to allow sound extrapolation to the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433342     DOI: 10.1517/17425255.4.4.363

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  18 in total

1.  Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  J Pharmacol Exp Ther       Date:  2011-12-21       Impact factor: 4.030

2.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

3.  Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; K Münch; J Segrestaa; T Pfeifer; A Treiber; Mf Fromm
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

4.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Authors:  Abraham J Wilhelm; Peer de Graaf; Agnes I Veldkamp; Jeroen J W M Janssen; Peter C Huijgens; Eleonora L Swart
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

5.  Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 7.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

8.  Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs.

Authors:  N D Pfeifer; S L Goss; B Swift; G Ghibellini; M Ivanovic; W D Heizer; L M Gangarosa; K L R Brouwer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-02

Review 9.  Inroads to predict in vivo toxicology-an introduction to the eTOX Project.

Authors:  Katharine Briggs; Montserrat Cases; David J Heard; Manuel Pastor; François Pognan; Ferran Sanz; Christof H Schwab; Thomas Steger-Hartmann; Andreas Sutter; David K Watson; Jörg D Wichard
Journal:  Int J Mol Sci       Date:  2012-03-21       Impact factor: 6.208

10.  Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.

Authors:  Marc Le Vee; Elodie Jouan; Bruno Stieger; Valérie Lecureur; Olivier Fardel
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.